Lysis of human immunodeficiency virus type 1 antigen-expressing cells by CD4 and CD8 T cells ex vivo. 1996

M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
Department of Internal Medicine, and Medical Policlinic, University of Würzburg, Germany.

The aim of this study was to investigate the extent of lysis mediated by cytotoxic T lymphocytes (CTL) directed against human immunodeficiency virus (HIV) type 1 gag protein and envelope glycoprotein in peripheral blood mononuclear cells (PBMC) from HIV-1-infected subjects and to compare it with nonspecific envelope glycoprotein-directed cytotoxicity involving CD4 T cells. Most seropositive subjects exhibited antigen-specific cytotoxicity directed at one or both viral antigens in unstimulated or in vitro-stimulated PBMC (or both) mediated by CD8 T cells. In addition, all donors, including seronegative control persons, exhibited nonspecific calcium-independent cytotoxicity involving CD4 T cells and envelope glycoprotein-expressing cells. No calcium-dependent, antigen-specific CD4 T cell-mediated cytolysis was detected. In seropositive subjects, the vigor of nonspecific cytotoxicity was comparable to lysis by antigen-specific CD8 CTL and suggests that it may contribute to lysis of HIV-infected cells in vitro and in vivo.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002472 Cell Transformation, Viral An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus. Transformation, Viral Cell,Viral Cell Transformation,Cell Transformations, Viral,Transformations, Viral Cell,Viral Cell Transformations
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
September 2000, Journal of virology,
M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
November 1997, Pediatric research,
M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
December 1998, Immunology letters,
M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
September 1996, Journal of virology,
M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
January 1994, Journal of virology,
M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
November 1998, Journal of virology,
M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
November 1998, AIDS research and human retroviruses,
M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
September 2004, Journal of virology,
M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
January 1992, Current topics in microbiology and immunology,
M Heinkelein, and I Euler-König, and H Klinker, and H Rückle-Lanz, and C Jassoy
January 2023, Frontiers in immunology,
Copied contents to your clipboard!